Sunitinib + Docetaxel as Second-line Treatment in Gastric Cancer

NCT01238055 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

116

Enrollment

OTHER

Sponsor class

Conditions

Advanced Gastric Cancer

Interventions

DRUG: Docetaxel + Sunitinib
DRUG: Docetaxel only

Sponsor

Samsung Medical Center